HU180882B - Process for preparing a composition containing factor ix further factor ii and x from plasma - Google Patents
Process for preparing a composition containing factor ix further factor ii and x from plasma Download PDFInfo
- Publication number
- HU180882B HU180882B HU78MO1022A HUMO001022A HU180882B HU 180882 B HU180882 B HU 180882B HU 78MO1022 A HU78MO1022 A HU 78MO1022A HU MO001022 A HUMO001022 A HU MO001022A HU 180882 B HU180882 B HU 180882B
- Authority
- HU
- Hungary
- Prior art keywords
- factor
- plasma
- copolymer
- polyelectrolyte
- maleic anhydride
- Prior art date
Links
- 229960004222 factor ix Drugs 0.000 title claims description 25
- 239000000203 mixture Substances 0.000 title description 12
- 238000004519 manufacturing process Methods 0.000 title 1
- 108010076282 Factor IX Proteins 0.000 claims abstract description 26
- 229920000867 polyelectrolyte Polymers 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims abstract description 10
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000005977 Ethylene Substances 0.000 claims abstract description 7
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 21
- 229920001577 copolymer Polymers 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 108010094028 Prothrombin Proteins 0.000 claims description 9
- -1 dimethylaminopropyl Chemical group 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 238000004132 cross linking Methods 0.000 claims description 6
- KMBPCQSCMCEPMU-UHFFFAOYSA-N n'-(3-aminopropyl)-n'-methylpropane-1,3-diamine Chemical compound NCCCN(C)CCCN KMBPCQSCMCEPMU-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 3
- 108010014173 Factor X Proteins 0.000 claims 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 2
- 239000003792 electrolyte Substances 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 abstract description 7
- 125000000524 functional group Chemical group 0.000 abstract description 6
- 230000007717 exclusion Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 102100027378 Prothrombin Human genes 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 229940039716 prothrombin Drugs 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 108010054218 Factor VIII Proteins 0.000 description 5
- 102000001690 Factor VIII Human genes 0.000 description 5
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 229960000301 factor viii Drugs 0.000 description 5
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 4
- 239000003114 blood coagulation factor Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical group CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 102100023804 Coagulation factor VII Human genes 0.000 description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 229940019700 blood coagulation factors Drugs 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229940012413 factor vii Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- KPYCVQASEGGKEG-UHFFFAOYSA-N 3-hydroxyoxolane-2,5-dione Chemical compound OC1CC(=O)OC1=O KPYCVQASEGGKEG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000008064 anhydrides Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010261 blood fractionation Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/818,920 US4081432A (en) | 1977-07-25 | 1977-07-25 | Method of separating a Factor IX preparation from plasma using ethylene-maleic anhydride polymers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HU180882B true HU180882B (en) | 1983-05-30 |
Family
ID=25226755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU78MO1022A HU180882B (en) | 1977-07-25 | 1978-07-21 | Process for preparing a composition containing factor ix further factor ii and x from plasma |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US4081432A (enExample) |
| EP (1) | EP0000651B1 (enExample) |
| JP (1) | JPS5426322A (enExample) |
| AT (1) | AT359645B (enExample) |
| AU (1) | AU517885B2 (enExample) |
| CA (1) | CA1107649A (enExample) |
| DE (1) | DE2861573D1 (enExample) |
| ES (1) | ES471857A1 (enExample) |
| HU (1) | HU180882B (enExample) |
| IL (1) | IL55194A0 (enExample) |
| IT (1) | IT1097302B (enExample) |
| MX (1) | MX5405E (enExample) |
| PT (1) | PT68337B (enExample) |
| RO (1) | RO75338A (enExample) |
| SU (1) | SU841572A3 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1603244A (en) * | 1977-05-20 | 1981-11-18 | Max Planck Gesellschaft | Medicaments for the suppression of pathological processes |
| ES471858A1 (es) * | 1977-07-25 | 1979-02-01 | Monsanto Co | Un metodo para separar el factor especifico de coagulacion de la sangre de una mezcla con otras proteinas de la sangre en un medio fluido |
| FR2472390A1 (fr) * | 1979-05-04 | 1981-07-03 | Merieux Inst | Procede de preparation de concentres de complexe prothrombinique hautement purifies, et concentres obtenus |
| SE448945B (sv) * | 1979-12-20 | 1987-03-30 | Blombaeck E G B | Forfarande for rening och /eller koncentrering av faktor viii-komplexet |
| AT368883B (de) | 1980-07-22 | 1982-11-25 | Immuno Ag | Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen |
| DE3045153A1 (de) * | 1980-11-29 | 1982-07-08 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x |
| US4435318A (en) | 1981-05-22 | 1984-03-06 | Ionics, Incorporated | Electrodialysis preparation of purified AHF concentrate |
| US4447416A (en) * | 1982-04-28 | 1984-05-08 | American National Red Cross | Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy |
| US4397841A (en) * | 1982-06-28 | 1983-08-09 | Monsanto Company | Production of blood coagulation factor VIII:C |
| US4382028A (en) * | 1982-07-19 | 1983-05-03 | Monsanto Company | Separation of plasma proteins from cell culture systems |
| US5055557A (en) * | 1983-03-04 | 1991-10-08 | Scripps Clinic & Research Foundation | Ultrapurification of factor IX and other vitamin K-dependent proteins |
| US5614500A (en) * | 1983-03-04 | 1997-03-25 | The Scripps Research Institute | Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography |
| US4786726A (en) * | 1986-01-06 | 1988-11-22 | Blood Systems, Inc. | Factor IX therapeutic blood product, means and methods of preparing same |
| DE3627762A1 (de) * | 1986-08-16 | 1988-02-18 | Behringwerke Ag | Verfahren zur herstellung einer prothrombin-armen praeparation vitamin k-abhaengiger gerinnungsfaktoren, sowie ein danach erhaeltliches mittel |
| ZA877535B (en) * | 1986-10-09 | 1988-04-11 | F. Hoffmann-La Roche & Co. Aktiengesellschaft | Factor ix-peptides |
| KR100447685B1 (ko) * | 1995-08-28 | 2004-12-03 | 세키스이 가가쿠 고교 가부시키가이샤 | 혈청또는혈장분리용조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3554985A (en) * | 1963-01-02 | 1971-01-12 | Monsanto Co | Cross-linked copolymer polyelectrolytes based on alpha,beta-ethylenically unsaturated acids |
| US3717708A (en) * | 1968-10-24 | 1973-02-20 | Cutter Lab | Blood coagulation complex |
| US3555001A (en) * | 1969-05-29 | 1971-01-12 | Monsanto Co | Process for the fractionation of plasma and serum using water-insoluble polyelectrolytes containing diloweralkylaminoloweralkylimide groups |
| US3682881A (en) * | 1970-10-02 | 1972-08-08 | Baxter Laboratories Inc | Fractionation of plasma using glycine and polyethylene glycol |
| IL42254A (en) * | 1973-05-13 | 1977-03-31 | Yeda Res & Dev | Polymeric carrier for biologically active proteins and biologically active substances based on these |
| US3920625A (en) * | 1973-06-19 | 1975-11-18 | Kabi Ab | Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates |
| DE2534603C2 (de) * | 1975-08-02 | 1984-10-31 | Basf Ag, 6700 Ludwigshafen | Verfahren zur Herstellung von Copolymerisaten mit N-Dialkyl-N-amido-Gruppen |
-
1977
- 1977-07-25 US US05/818,920 patent/US4081432A/en not_active Expired - Lifetime
-
1978
- 1978-07-19 ES ES471857A patent/ES471857A1/es not_active Expired
- 1978-07-21 AU AU38243/78A patent/AU517885B2/en not_active Expired
- 1978-07-21 MX MX787273U patent/MX5405E/es unknown
- 1978-07-21 RO RO7894744A patent/RO75338A/ro unknown
- 1978-07-21 EP EP78300177A patent/EP0000651B1/en not_active Expired
- 1978-07-21 DE DE7878300177T patent/DE2861573D1/de not_active Expired
- 1978-07-21 HU HU78MO1022A patent/HU180882B/hu not_active IP Right Cessation
- 1978-07-21 IL IL55194A patent/IL55194A0/xx not_active IP Right Cessation
- 1978-07-21 IT IT26005/78A patent/IT1097302B/it active
- 1978-07-21 AT AT531778A patent/AT359645B/de not_active IP Right Cessation
- 1978-07-21 PT PT68337A patent/PT68337B/pt unknown
- 1978-07-21 JP JP8930678A patent/JPS5426322A/ja active Granted
- 1978-07-21 SU SU782639950A patent/SU841572A3/ru active
- 1978-07-24 CA CA307,999A patent/CA1107649A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| EP0000651A1 (en) | 1979-02-07 |
| ES471857A1 (es) | 1979-02-01 |
| JPS6154008B2 (enExample) | 1986-11-20 |
| SU841572A3 (ru) | 1981-06-23 |
| EP0000651B1 (en) | 1982-01-27 |
| US4081432A (en) | 1978-03-28 |
| AT359645B (de) | 1980-11-25 |
| PT68337B (pt) | 1994-02-25 |
| DE2861573D1 (en) | 1982-03-11 |
| IL55194A0 (en) | 1978-09-29 |
| CA1107649A (en) | 1981-08-25 |
| IT1097302B (it) | 1985-08-31 |
| MX5405E (es) | 1983-07-13 |
| RO75338A (ro) | 1980-11-30 |
| ATA531778A (de) | 1980-04-15 |
| AU517885B2 (en) | 1981-09-03 |
| AU3824378A (en) | 1980-01-24 |
| IT7826005A0 (it) | 1978-07-21 |
| PT68337A (en) | 1978-08-01 |
| JPS5426322A (en) | 1979-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU180882B (en) | Process for preparing a composition containing factor ix further factor ii and x from plasma | |
| DE69227055T2 (de) | Verfahren zur Herstellung in industriellem Massstab eines Konzentrates von hochgereinigtem, standardisiertem humanen von Willebrand Faktor, das für therapeutische Anwendung geeignet ist | |
| US3925344A (en) | Plasma protein substitute | |
| US4414976A (en) | Tissue adhesive | |
| US4297344A (en) | Blood coagulation factors and process for their manufacture | |
| US4160025A (en) | Method of producing a blood-coagulation-promoting preparation from human blood plasma | |
| US4661471A (en) | Method of inhibiting and inducing human platelet aggregation | |
| JPH11509721A (ja) | 高純度フォンビルブラント因子の入手方法 | |
| CA2006658C (en) | An anticoagulant substance obtained from urine | |
| US4331766A (en) | Collagen solution, process for its manufacture and its use | |
| SU1375116A3 (ru) | Способ получени фактора УШ:С свертывани крови | |
| CA1338395C (en) | Pharmaceutical containing tissue protein pp4, a process for the pasteurization of pp4, and the use of pp4 | |
| EP0107688B1 (en) | Processes for the production of blood products | |
| DE69026513T2 (de) | Polyhämoglobin durch purinderivate und glutathion stabilisiert | |
| US4097473A (en) | Production of serum albumin | |
| JPS5932443B2 (ja) | トロンビン阻止物質、その製造方法及び該物質を含有するトロンビン阻止用薬剤組成物 | |
| EP0245875A2 (en) | Method of purifying factor VIII | |
| WO1989010135A1 (en) | Hybrid peptides and methods of their use | |
| EP0412466B1 (de) | Verfahren zur Herstellung eines stabilen Faktors VIII | |
| EP0401232B1 (en) | A process for pasteurization of aqueous solutions of factor viii | |
| CA1297634C (en) | Anticoagulating substance and preparation process thereof | |
| WO1994004176A1 (en) | Novel peptides for heparin anticoagulation reversal | |
| Boisson-Vidal et al. | Adsorption of human antibodies to factor VIII: C to insoluble modified polystyrene from plasma | |
| Götze et al. | The induction of macrophage spreading by factor B of the properdin system | |
| JPS6383670A (ja) | 血液検査用容器 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HU90 | Patent valid on 900628 | ||
| HMM4 | Cancellation of final prot. due to non-payment of fee |